Vyant Bio, Inc.

Thank you for standing by, and welcome to the ViantBio Third Quarter 2022 Earnings Conference Call and Webcast. Yesterday, Tuesday, November 15, 2022, the company issued a press release summarizing the results for the third quarter of 2022. Today's discussion will provide an overview of activities in the third quarter and nine-month period ended September 30, 2022. Today's call is being recorded and a replay of the webcast will be available on the ViantBio website following today's call at www.viantbio.com. Alternatively, the link can be sent to you by contacting ir at viantbio.com. All participants on this call will be in a listen-only mode during the presentation. The presentation will be followed by a question-and-answer session. At this time, I will now turn the call over to Jay Roberts, Chief Executive Officer of ViantBio. Please go ahead, sir.

Thank you, operator. Thanks to all of you for joining us today. In our second quarter call, we have been very active progressing our scientific research and development activities while recently completing the day passage of our U.S. operations of VivoPharm. We are delighted to speak with you today to show enthusiasm and to talk about some recent accomplishments and awards, and give you some insight into how we envision the near-term future of ViantBio while providing our financial results in the third quarter in the nine months of 2022. That's such, and the colleague today is ViantBio's Chief Financial Officer, Andy LaFrance, and our Chief Scientific Officer, Dr. Robert Fermot. Following the Safe Harbor statement, I will start out with a brief overview of ViantBio, and describe the corporate admission as we have accomplished so far this year. Then, Dr. Pramod will provide an overview and an update on recent scientific achievements made this year and the vision ahead. Finally, Andy LaFrance will take us through a brief financial update and discuss key accounting matters for the reporting period. I will make some closing remarks, and then we will open up the line to answer your questions. I will now turn the call over to our CFO, Andy LaFrance.

Thank you, Jay, and welcome to all. We'd like to remind everyone that various comments about future expectations, plans, and prospects constitute forward-looking statements for purposes of safe harbor provisions under the Private Securities Litigation Reform Act of 1995. VAIO cautions that these forward-looking statements are subject to risks and uncertainties that may cause are asked results to differ materially from those indicated, including risks described in the company's filings with the Securities and Exchange Commission. Any forward-looking statements made on this contact call speak only of today's date, Wednesday, November 16, 2022, and VIO does not intend to update any of these forward-looking statements to reflect events or circumstances that would occur after today's date. This conference call is also being recorded for audio rebroadcast on ViantBio's website at www.viantbio.com. With that, I would like to turn the call back over to Jay Roberts. Jay?